DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): Mechanistic Evidence for Chloride Channel Blockade and Translational Applications

Executive Summary: DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) is a well-characterized anion transport inhibitor, most notably blocking ClC-Ka channels with an IC50 of 100 μM and bacterial ClC-ec1 exchangers at approximately 300 μM, as shown under in vitro conditions (https://www.apexbt.com/dids.html). It exerts vasodilatory effects on cerebral artery smooth muscle cells (IC50: 69 ± 14 μM) and modulates TRPV1 channels in an agonist-dependent manner (https://doi.org/10.1016/j.celrep.2022.110490). DIDS enhances tumor suppression when combined with hyperthermia and amiloride, and shows neuroprotective effects via ClC-2 channel inhibition in ischemia-hypoxia models. Its insolubility in water, ethanol, and DMSO at standard concentrations, but solubility above 10 mM in DMSO with warming or sonication, requires precise workflow handling. These claims are supported by peer-reviewed studies, product documentation, and authoritative reviews (https://dznep.com/index.php?g=Wap&m=Article&a=detail&id=15306).

Biological Rationale

Chloride channels are central to physiological processes such as cell volume regulation, neuronal excitability, and vascular tone. Dysregulation of anion transport is implicated in cancer progression, neurodegeneration, and vascular dysfunction (https://doi.org/10.1016/j.celrep.2022.110490). DIDS, as a selective chloride channel blocker, enables targeted investigation of ClC-Ka, ClC-ec1, and ClC-2 channel roles in these systems. Its ability to inhibit spontaneous transient inward currents (STICs) in muscle cells makes it a reference compound in electrophysiology. APExBIO's DIDS (B7675) is widely adopted in research due to its characterized selectivity and reproducible solubility profile.

Mechanism of Action of DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid)

DIDS acts as a covalent inhibitor of anion transporters and chloride channels by modifying lysine residues involved in channel gating. In human and bacterial systems, DIDS exhibits a concentration-dependent blockade of ClC-Ka (IC50: 100 μM) and ClC-ec1 (IC50: ~300 μM) (https://www.apexbt.com/dids.html). In vascular smooth muscle, DIDS reduces STICs and induces vasodilation, with a reported IC50 of 69 ± 14 μM in pressure-constricted cerebral arteries. DIDS also modulates TRPV1 channel function in dorsal root ganglion neurons, enhancing agonist-induced currents. Neuroprotection is achieved via inhibition of voltage-gated ClC-2 channels, leading to reduced reactive oxygen species (ROS), iNOS, TNF-α, and caspase-3 positive cells in ischemia-hypoxia models. In cancer models, DIDS potentiates hyperthermia-induced tumor growth suppression, particularly when combined with amiloride (https://doi.org/10.1016/j.celrep.2022.110490).

Evidence & Benchmarks

• DIDS inhibits the ClC-Ka chloride channel with an IC50 of 100 μM under in vitro conditions (https://www.apexbt.com/dids.html).
• Bacterial ClC-ec1 Cl-/H+ exchanger is blocked by DIDS with an IC50 of approximately 300 μM (https://www.apexbt.com/dids.html).
• DIDS induces vasodilation in pressure-constricted cerebral artery smooth muscle cells (IC50: 69 ± 14 μM) (https://doi.org/10.1016/j.celrep.2022.110490).
• Enhancement of TRPV1 channel currents by DIDS occurs in an agonist-dependent manner in DRG neurons (https://doi.org/10.1016/j.celrep.2022.110490).
• DIDS reduces ischemia-hypoxia-induced white matter damage in neonatal rats by inhibiting ClC-2 and attenuating ROS, iNOS, TNF-α, and caspase-3 positive cells (https://doi.org/10.1016/j.celrep.2022.110490).
• In tumor models, DIDS combined with amiloride and hyperthermia prolongs tumor growth delay in vivo (https://doi.org/10.1016/j.celrep.2022.110490).
• DIDS modifies endoplasmic reticulum stress responses implicated in metastatic reprogramming (https://doi.org/10.1016/j.celrep.2022.110490).

This article extends the mechanistic discussion in this DZNEP article by providing atomic, citation-backed evidence for DIDS's molecular targets and translational benchmarks.

For additional workflow guidance, see DIDS: Workflow Integration, which this article updates with new quantitative data and mechanistic context.

Applications, Limits & Misconceptions

DIDS is validated for research in chloride channel function, vascular physiology, cancer hyperthermia, and neuroprotection. It is not recommended for use as a therapeutic in humans. Its insolubility in standard solvents limits its use in some cell-based or in vivo protocols. For mechanistic insights on DIDS in ER stress modulation and metastatic adaptation, see this mechanistic overview, which this article clarifies by specifying tested concentrations and biological endpoints.

Common Pitfalls or Misconceptions

• Not water soluble: DIDS is insoluble in water, ethanol, and DMSO at concentrations below 10 mM; improper preparation may cause precipitation and loss of activity.
• Non-selectivity at high concentrations: At concentrations above 1 mM, DIDS may inhibit additional anion transporters or unrelated channels.
• Limited long-term stability: Stock solutions are not stable for long-term storage above -20°C or in solution; fresh preparation is advised.
• Not a clinical drug: DIDS is for research use only; no approval exists for clinical application in humans.
• pH and temperature effects: Channel inhibition kinetics may vary with buffer pH and temperature; always report and control these parameters.

Workflow Integration & Parameters

DIDS (APExBIO B7675) is supplied as a solid. For optimal use, dissolve in DMSO at concentrations >10 mM, applying gentle warming (37°C) or ultrasonic bath as needed. Stock solutions should be aliquoted and stored at -20°C, avoiding repeated freeze-thaw cycles. For in vitro assays, use final working concentrations between 10–300 μM, adjusting for channel target and cellular context. In vascular and neuroprotection assays, titrate DIDS to match reported IC50 values for specific channels. Always include appropriate controls for solvent and off-target effects.

Conclusion & Outlook

DIDS remains a gold standard for mechanistic dissection of chloride channel function in basic and translational research. Its atomic-level mechanism, validated by robust dose-response data and cross-species efficacy, supports use in vascular, neurological, and cancer models. Ongoing research explores DIDS's role in modulating ER stress and metastatic states, as highlighted in recent landmark studies (https://doi.org/10.1016/j.celrep.2022.110490). Researchers should adhere to precise solubility and storage recommendations for reproducibility. For reagent acquisition and full specifications, refer to the DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) product page. APExBIO provides validated quality and documentation for research applications.